Personalized Antisense Oligonucleotide Therapy for A Single Participant With ATN1 Gene Mutation

NCT06706388 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

1

Enrollment

OTHER

Sponsor class

Conditions

Dentatorubral-Pallidoluysian Atrophy

Interventions

DRUG: nL-ATN1-002

Sponsor

n-Lorem Foundation

Collaborators

[object Object]